for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioLife Solutions Inc

BLFS.OQ

Latest Trade

16.89USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

9.19

 - 

22.38

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
16.89
Open
--
Volume
--
3M AVG Volume
3.97
Today's High
--
Today's Low
--
52 Week High
22.38
52 Week Low
9.19
Shares Out (MIL)
19.00
Market Cap (MIL)
310.32
Forward P/E
136.08
Dividend (Yield %)
--

Next Event

Biolife Solutions Inc Annual Shareholders Meeting

Latest Developments

More

Biolife Solutions Q2 Adjusted Earnings Per Share $0.04

BioLife Solutions To Acquire SAVSU Technologies

BioLife Solutions Q4 Earnings Per Share $0.04

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BioLife Solutions Inc

BioLife Solutions, Inc. (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products. Its products include HypoThermosol FRS, CryoStor, BloodStor, Cell Thawing Media, PrepaStor and biologistex cold-chain management service.

Industry

Medical Equipment & Supplies

Contact Info

3303 Monte Villa Pkwy Ste 310

+1.425.4011400

https://biolifesolutions.com/

Executive Leadership

Raymond Wayne Cohen

Independent Chairman of the Board

Michael Rice

President, Chief Executive Officer, Director

Roderick de Greef

Chief Financial Officer, Secretary, IR Contact Officer

Aby J. Mathew

Senior Vice President, Chief Technology Officer

Karen A. Foster

Vice President - Operations

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.540

2017

-0.210

2018

0.140

2019(E)

0.120
Price To Earnings (TTM)
120.07
Price To Sales (TTM)
13.36
Price To Book (MRQ)
6.55
Price To Cash Flow (TTM)
83.00
Total Debt To Equity (MRQ)
0.05
LT Debt To Equity (MRQ)
0.02
Return on Investment (TTM)
9.85
Return on Equity (TTM)
9.22

Latest News

Latest News

BRIEF-Casdin Capital To Become Shareholder In Biolife Solutions

* CASDIN CAPITAL LLC, ENTERED INTO AN AGREEMENT TO PURCHASE 1,000,000 BIOLIFE SOLUTIONS SHARES IN PRIVATE DEAL Source text for Eikon: Further company coverage:

BRIEF-BioLife Solutions Announces Preliminary Q1 Revenue Of $3.8 Mln, Up 61 Pct

* FOR 2018 BIOPRESERVATION MEDIA REVENUE EXPECTED TO RANGE BETWEEN $14.5 MILLION TO $15.5 MILLION

BRIEF-BioLife Solutions Q4 Loss Per Share $0.05

* BIOLIFE SOLUTIONS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Biolife Solutions Executes OEM Agreement With MilliporeSigma

* BIOLIFE SOLUTIONS EXECUTES OEM AGREEMENT WITH MILLIPORESIGMA Source text for Eikon: Further company coverage:

BRIEF-Biolife Solutions Says Co And Savsu Technologies Amended Their Arrangement With Respect To JV

* BIOLIFE SOLUTIONS SAYS ON JAN 22 CO AND SAVSU TECHNOLOGIES AMENDED THEIR ARRANGEMENT WITH RESPECT TO THEIR JV, BIOLOGISTEX- SEC FILING

BRIEF-Biolife Solutions Executes Supply Agreement With Iovance Biotherapeutics

* BIOLIFE SOLUTIONS EXECUTES SUPPLY AGREEMENT WITH IOVANCE BIOTHERAPEUTICS

BRIEF-Biolife Solutions Executes Additional Long-Term Supply Agreement With Leading T Cell Therapy Customer

* BIOLIFE SOLUTIONS EXECUTES ADDITIONAL LONG-TERM SUPPLY AGREEMENT WITH LEADING T CELL THERAPY CUSTOMER Source text for Eikon: Further company coverage:

BRIEF-BioLife Solutions posts Q3 loss per share $0.03

* Biolife Solutions announces third quarter 2017 financial results

BRIEF-Biolife Solutions to report Q3 results and provide business update on Nov 9

* Biolife Solutions to report third quarter 2017 financial results and provide business update on November 9, 2017 Source text for Eikon: Further company coverage:

BRIEF-BioLife Solutions CryoStor cell freeze media embedded in Cellular Biomedicine Group clinical trial of AlloJoin

* BioLife Solutions CryoStor cell freeze media embedded in Cellular Biomedicine Group clinical trial of AlloJoin Source text for Eikon: Further company coverage:

BRIEF-BioLife Solutions executes supply agreement with Celyad for CryoStor

* Biolife Solutions executes supply agreement with Celyad for CryoStor use in natural killer receptor based t-cell (nkr-t) platform targeting solid tumors and blood cancers

BRIEF-Biolife Solutions modifies existing credit facility

* Biolife Solutions Inc - has reached an agreement with wavi holding to modify its existing credit facility effective June 30, 2017

BRIEF-Biolife Solutions executes supply agreement with Adaptimmune for Cryostor

* Biolife solutions executes supply agreement with adaptimmune for cryostor® use in spear t-cell platform

BRIEF-Biolife Solutions reports Q1 loss per share $0.07

* Biolife Solutions Inc - qtrly product revenue $2.4 million versus $1.9 million; qtrly loss per share $0.07

BRIEF-Biolife Solutions posts 4th quarter, full year 2016 results

* Biolife solutions reports 4th quarter and full year 2016 results

BRIEF-Biolife Solutions says expects $1.6 mln-$2mln annual expense reduction from Biologistex JV restructuring - SEC filing

* Biolife Solutions Inc - anticipate $1.6 mln-$2mln annual expense reduction from Biologistex JV restructuring - SEC filing Source text: (http://bit.ly/2lW1TgE) Further company coverage:

BRIEF-Biolife Solutions announces 2016 revenue growth of 28 pct

* Biolife solutions sees 2017 biopreservation media revenue growth of 20-25 pct over 2016; revenue in excess of $10 million

BRIEF-Biolife solutions amends existing credit facility

* Reached agreement to extend maturity date and repayment schedule of its outstanding $4 million credit facility

BRIEF-Biolife Solutions reports Q3 product sales $2.1 million

* Biolife solutions reports record results for third quarter 2016

BRIEF-Biolife Solutions to report Q3 financial results and provide business update on Nov. 10,

* Biolife Solutions to report third quarter 2016 financial results and provide business update on November 10, 2016 Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up